Navigation Links
Vermillion Announces Effectiveness of Reverse Stock Split
Date:3/3/2008

FREMONT, Calif., March 3 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML) (the "Company"), a high-value molecular diagnostics company, announced today that on February 29, 2008, the Company filed its Third Amended and Restated Certificate of Incorporation, which effects a 1-for-10 reverse stock split of the Company's outstanding common stock. The reverse stock split will be effective with respect to stockholders of record upon the close of business today, March 3, 2008.

The common stock will trade on the NASDAQ Capital Market under the symbol "VRMLD" for 20 trading days beginning March 4, 2008 to designate that it is trading on a post-reverse split basis, and will resume trading under the symbol "VRML" after the 20-day period has expired.

"With this reverse stock split now effective, we believe that a broader group of potential investors can purchase our shares and will recognize the value of our diagnostic programs addressing complex diseases," said Gail S. Page, President and CEO of Vermillion.

As a result of the reverse stock split, each ten shares of common stock will be combined and reclassified into one share of common stock and the total number of shares outstanding will be reduced from approximately 63.8 million shares to approximately 6.4 million shares.

The Company's transfer agent, Wells Fargo Shareowner Services, will send instructions to stockholders of record regarding the exchange of certificates for common stock.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collab
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
2. Vermillion Receives NASDAQ Notice of Non-Compliance
3. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
6. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
7. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
8. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
9. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
10. MiMedx Announces Brian J. Splan as President
11. Boston Scientific Announces European Approval of New Heart Failure Lead
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, the White House will ... from across the United States to talk about their experiences with innovation and present ... to be among the attendees. , One of the day’s aims is to grow ...
(Date:8/3/2015)... 3, 2015 At the 11th ... waved the shortfall of Jude Liversage,s ... for the first time.      (Photo: ... ) The Selective Dorsal Rhizotomy (SDR) ... to carry out his wish to kick a ball ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech ... to its comprehensive line of analytical laboratory equipment. With optimized features, such as ... provide a chemically resistant and maintenance-free solution for a broad range of vacuum ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Sterlitech Launches New Line of Vacuum Pumps 2
... TGH to Enhance Clinical Skills,Development, DENVER, Nov. ... partnership with the University of South Florida (USF) ... Health hospital,partners and for local and national health ... Center is located at Tampa,General Hospital, a major ...
... 10 NeurogesX, Inc.,(Nasdaq: NGSX ), a ... management therapies, announced today that,Anthony DiTonno, President and ... Rodman & Renshaw 10th Annual Healthcare Conference in ... DiTonno and Stephen Ghiglieri,Chief Financial Officer, will also ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
Cached Biology Technology:Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... attained very promising results on their initial investigations of a ... mass spectrometry of a single drop of blood serum, the ... of the patients tested. The results can be found online ... . "Because ovarian cancer is a disease of ...
... As much as 12 percent of the worlds human-caused greenhouse ... charcoal-like substance made from plants and other organic materials. Thats ... and materials were burned to generate energy, concludes a study ... calculations show that biochar can play a significant role in ...
... marine mosasaur Platecarpus , lived in the Cretaceous Period some ... an eel. That theory is debunked in a new paper published ... of scientists have reconceived the animal,s morphology, or body plan, based ... Los Angeles County. The paper was co-authored by ...
Cached Biology News:Initial trials on new ovarian cancer tests exhibit extremely high accuracy 2Charcoal takes some heat off global warming 2Charcoal takes some heat off global warming 3Charcoal takes some heat off global warming 4Charcoal takes some heat off global warming 5Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: